Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hepatitis C Draft Guidance Cites Utility Of Unapproved HCV-RNA Tests

This article was originally published in The Gray Sheet

Executive Summary

Clinical trials of hybridization assays for monitoring hepatitis C viral RNA may use other unapproved HCV-RNA assays to corroborate test results, provided supporting data is submitted, FDA indicates in a recently released draft guidance.

You may also be interested in...



HEPATITIS C RNA PANEL SHOULD BE DEVELOPED TO TEST NEW ASSAYS, PANEL SAYS; DCLD DEVELOPING GUIDANCE ON VARIOUS HEPATITIS A, B, C TESTS AND INDICATIONS

FDA should develop a panel of hepatitis C virus RNA specimens to challenge new qualitative HCV RNA assays, the agency's Microbiology Devices Panel recommended at its Feb. 12 meeting in Gaithersburg, Maryland. The group was convened to assist FDA's Center for Devices and Radiological Health in efforts to develop a guidance that will prescribe clinical study guidelines for hepatitis A, B, or C tests for diagnosis and/or monitoring indications.

What Lies Ahead: COVID-19 Vaccination Challenges

The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.

P&G: Sales Growth Strongest When Rising Tide Floats All Competitors Across All Categories

P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel